BR9611861A - Tratamento dos efeitos sobre o sistema nervoso central do hiv com vx-478 sozinho ou em combinação com azt ou 3tc - Google Patents

Tratamento dos efeitos sobre o sistema nervoso central do hiv com vx-478 sozinho ou em combinação com azt ou 3tc

Info

Publication number
BR9611861A
BR9611861A BR9611861A BR9611861A BR9611861A BR 9611861 A BR9611861 A BR 9611861A BR 9611861 A BR9611861 A BR 9611861A BR 9611861 A BR9611861 A BR 9611861A BR 9611861 A BR9611861 A BR 9611861A
Authority
BR
Brazil
Prior art keywords
azt
alone
treatment
combination
nervous system
Prior art date
Application number
BR9611861A
Other languages
English (en)
Inventor
Pravin Ramsewak Chaturvedi
Original Assignee
Vertex Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vertex Pharma filed Critical Vertex Pharma
Publication of BR9611861A publication Critical patent/BR9611861A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
    • A61K31/635—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide having a heterocyclic ring, e.g. sulfadiazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
BR9611861A 1995-12-05 1996-12-05 Tratamento dos efeitos sobre o sistema nervoso central do hiv com vx-478 sozinho ou em combinação com azt ou 3tc BR9611861A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/567,199 US5646180A (en) 1995-12-05 1995-12-05 Treatment of the CNS effects of HIV
PCT/US1996/019447 WO1997020554A1 (en) 1995-12-05 1996-12-05 Treatment of the cns effects of hiv with vx-478, alone or in combination with azt or 3tc

Publications (1)

Publication Number Publication Date
BR9611861A true BR9611861A (pt) 1999-05-18

Family

ID=24266147

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9611861A BR9611861A (pt) 1995-12-05 1996-12-05 Tratamento dos efeitos sobre o sistema nervoso central do hiv com vx-478 sozinho ou em combinação com azt ou 3tc

Country Status (23)

Country Link
US (1) US5646180A (pt)
EP (1) EP0866696B1 (pt)
JP (1) JP2000501713A (pt)
KR (1) KR19990071750A (pt)
CN (1) CN1203530A (pt)
AP (1) AP864A (pt)
AT (1) ATE279922T1 (pt)
AU (1) AU722850B2 (pt)
BR (1) BR9611861A (pt)
CA (1) CA2238471A1 (pt)
CZ (1) CZ291994B6 (pt)
DE (1) DE69633680T2 (pt)
ES (1) ES2231828T3 (pt)
HU (1) HUP9903673A3 (pt)
NO (1) NO317837B1 (pt)
NZ (1) NZ324603A (pt)
OA (1) OA10691A (pt)
PL (1) PL187747B1 (pt)
PT (1) PT866696E (pt)
RU (1) RU2203658C2 (pt)
UA (1) UA61902C2 (pt)
WO (1) WO1997020554A1 (pt)
ZA (1) ZA9610139B (pt)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6107499A (en) * 1988-02-26 2000-08-22 Neuromedica, Inc. Dopamine analog amide
US5942253A (en) 1995-10-12 1999-08-24 Immunex Corporation Prolonged release of GM-CSF
US6576636B2 (en) 1996-05-22 2003-06-10 Protarga, Inc. Method of treating a liver disorder with fatty acid-antiviral agent conjugates
US5795909A (en) * 1996-05-22 1998-08-18 Neuromedica, Inc. DHA-pharmaceutical agent conjugates of taxanes
US6486136B1 (en) * 1996-06-25 2002-11-26 Smithkline Beecham Corporation Combinations comprising VX478, zidovudine and/or 1592U89 for use in the treatment of HIV
AP9801419A0 (en) * 1996-06-25 1998-12-31 Glaxo Group Ltd Combination comprising VX478, zidovudine, FTC and or 3
ZA9710071B (en) * 1996-11-21 1998-05-25 Abbott Lab Pharmaceutical composition.
US6232333B1 (en) 1996-11-21 2001-05-15 Abbott Laboratories Pharmaceutical composition
NZ500868A (en) * 1997-05-17 2001-08-31 Glaxo Group Ltd Antiviral combinations comprising 1592U89 and HIV protease inhibitors
WO1998057648A1 (en) * 1997-06-16 1998-12-23 Vertex Pharmaceuticals Incorporated Methods of increasing the bioavailability of stable crystal polymorphs of a compound
US6576231B2 (en) * 1997-09-12 2003-06-10 Schering Ag Methods for treating HIV-Infected Patients by the Administration of GM-CSF and a protease inhibitor
US6197764B1 (en) 1997-11-26 2001-03-06 Protarga, Inc. Clozapine compositions and uses thereof
US5977174A (en) * 1997-11-26 1999-11-02 Neuromedica, Inc. Cholinergic compositions and uses thereof
US5955459A (en) * 1997-11-26 1999-09-21 Neuromedica, Inc. Fatty acid-antipsychotic compositions and uses thereof
US6153653A (en) * 1997-11-26 2000-11-28 Protarga, Inc. Choline compositions and uses thereof
US6436989B1 (en) 1997-12-24 2002-08-20 Vertex Pharmaceuticals, Incorporated Prodrugs of aspartyl protease inhibitors
US6309632B1 (en) * 1998-04-28 2001-10-30 Immunex Corporation Methods for treating HIV-infected patients by administering GM-CSF
US6875773B1 (en) * 1998-05-29 2005-04-05 Ben M. Dunn Combination therapy for treatment of FIV infection
US20090197827A1 (en) * 1998-05-29 2009-08-06 Dunn Ben M Combination Therapy for Treatment of FIV Infection
US7235583B1 (en) * 1999-03-09 2007-06-26 Luitpold Pharmaceuticals, Inc., Fatty acid-anticancer conjugates and uses thereof
US6417189B1 (en) 1999-11-12 2002-07-09 Gpi Nil Holdings, Inc. AZA compounds, pharmaceutical compositions and methods of use
DK1328213T3 (da) * 2000-10-16 2005-11-28 Conor Medsystems Inc Ekspanderbar medicinsk indretning til afgivelse af et nyttigt middel
ES2387562T3 (es) * 2001-03-23 2012-09-26 Luitpold Pharmaceuticals, Inc. Conjugados alcohol graso-medicamento
EP1427407A4 (en) 2001-03-23 2005-05-11 Luitpold Pharm Inc CONJUGATES BASED ON FATTY AMINES AND PHARMACEUTICAL AGENTS
EP2266590A3 (en) 2002-02-22 2011-04-20 Shire LLC Active agent delivery sytems and methods for protecting and administering active agents
US7871991B2 (en) 2004-07-27 2011-01-18 Gilead Sciences, Inc. Phosphonate analogs of HIV inhibitor compounds
AU2006206399B2 (en) * 2005-01-20 2012-04-05 University Of Rochester Compositions and methods relating to mitochondrial hyperpolarization in neurological disease
CA2634932A1 (en) * 2005-12-23 2007-07-05 University Of Rochester Treatment of neuroaids using inhibitors of glycogen synthase kinase (gsk)-3
US8642642B2 (en) * 2006-04-19 2014-02-04 Abbott Laboratories Heterocyclic arylsulphones suitable for treating disorders that respond to modulation of the serotonin 5HT6 receptor
CN102272134B (zh) 2008-12-09 2013-10-16 吉里德科学公司 Toll样受体调节剂
US20110223131A1 (en) 2010-02-24 2011-09-15 Gilead Sciences, Inc. Antiviral compounds
EP3110381B1 (en) 2014-02-28 2020-07-15 Attends Healthcare Products, Inc. Absorbent article with multi-layer folded absorbent core
WO2016001907A1 (en) 2014-07-02 2016-01-07 Prendergast Patrick T Mogroside iv and mogroside v as agonist/stimulator/un-blocking agent for toll-like receptor 4 and adjuvant for use in human/animal vaccine and to stimulate immunity against disease agents.
AU2015287773B2 (en) 2014-07-11 2018-03-29 Gilead Sciences, Inc. Modulators of toll-like receptors for the treatment of HIV
CA2997955A1 (en) 2015-09-15 2017-03-23 Gilead Sciences, Inc. Modulators of toll-like receptors for the treatment of hiv
MX2020012801A (es) 2018-05-28 2021-03-25 Attends Healthcare Products Inc Laminado con capa de sequedad para articulos absorbentes.

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IS2334B (is) * 1992-09-08 2008-02-15 Vertex Pharmaceuticals Inc., (A Massachusetts Corporation) Aspartyl próteasi hemjari af nýjum flokki súlfonamíða
AU5748194A (en) * 1992-12-11 1994-07-04 Vertex Pharmaceuticals Incorporated Mannitol derivatives and their use as inhibitors of aspartyl protease

Also Published As

Publication number Publication date
CA2238471A1 (en) 1997-06-12
AU1148697A (en) 1997-06-27
NO982556D0 (no) 1998-06-04
NO317837B1 (no) 2004-12-20
NZ324603A (en) 2000-08-25
NO982556L (no) 1998-06-04
HUP9903673A3 (en) 2000-08-28
ES2231828T3 (es) 2005-05-16
AP864A (en) 2000-08-11
KR19990071750A (ko) 1999-09-27
US5646180A (en) 1997-07-08
EP0866696A1 (en) 1998-09-30
JP2000501713A (ja) 2000-02-15
ATE279922T1 (de) 2004-11-15
CZ170898A3 (cs) 1998-09-16
HUP9903673A2 (hu) 2000-03-28
OA10691A (en) 2001-05-04
WO1997020554A1 (en) 1997-06-12
CZ291994B6 (cs) 2003-07-16
PL187747B1 (pl) 2004-09-30
DE69633680T2 (de) 2006-02-23
DE69633680D1 (de) 2004-11-25
AU722850B2 (en) 2000-08-10
AP9801340A0 (en) 1998-09-30
PT866696E (pt) 2005-03-31
UA61902C2 (en) 2003-12-15
EP0866696B1 (en) 2004-10-20
ZA9610139B (en) 1997-06-17
PL327061A1 (en) 1998-11-23
RU2203658C2 (ru) 2003-05-10
CN1203530A (zh) 1998-12-30

Similar Documents

Publication Publication Date Title
BR9611861A (pt) Tratamento dos efeitos sobre o sistema nervoso central do hiv com vx-478 sozinho ou em combinação com azt ou 3tc
PT817637E (pt) Combinacoes sinergeticas de zidovudina 1592u89 e 3tc ou ftc
FR2759581B1 (fr) Dispositif de traitement, notamment par moxa, de type acupressure
PT871619E (pt) Derivados de fenil-tiazol com propriedades anti-virus do herpesc
DK0876205T3 (da) Partikler med polymerkappe samt deres fremstilling
BR9301371A (pt) Dispositivo de iluminacao e/ou de sinalizacao utilizavel em situacao de neblina
BR9408062A (pt) Tratamento de distúrbios climatéricos com substratos e/ou doadores de óxido nitrico sintase
EE9800459A (et) Spiro-piperidiini derivaadid ja nende kasutamine terapeutiliste toimeainetena
BR9609831A (pt) Composições cosméticas e/ou farmacêuticas antipruríticas
BR9600300A (pt) Artigo e composição aquosa
BR9608253A (pt) Composição tópica para cuidado pessoal que contém copolímero enxertado de silicone terminado por alquenila ou estireno
BR9608309A (pt) Derivados de azacicloalcanos dua preparação e suas aplicações em terapêutica
DE59909860D1 (de) Anwendung von 5'-modifizierten nukleotiden in der molekularbiologie und medizin
BR9509925A (pt) Composição e uso da composição para prevenção ou tratamento de infecção por hiv-1
PT1030636E (pt) Artigo absorvente com propriedades aperfeicoadas de gestao dos excreta viscosos e fluidos
FI973185A (fi) Melatoniinin käyttö lääkeriippuvuudesta kärsivien potilaiden hoitoon
PT96225A (pt) Aquecedor de chumaceiras e similares
NO996496D0 (no) (S) 2-metylamino-2-fenyl-n-butyl 3,4,5-trimetoksybenzoat samt anvendelse av denne ved behandling av kronisk smerte
DE69637548D1 (de) MENSCHLICHE DNAse I VARIANTEN
BR9600346A (pt) Artigo de escrita ou de coloração
AR011099A1 (es) Microparticulas y su uso en la preparacion de medicamentos para el tratamiento de cancer.
DE69507677D1 (de) Hydrophile Acrylharze und diese enthaltende wässerige Beschichtungszusammensetzung
KR960004703U (ko) 컵받침 겸 컨솔 도어
BR9501749A (pt) Dispositivo para acolher e conter objetos arrendondados ou angulosos
BA95039A (bs) Set za prevenciju i terapiju bolne menstruacije

Legal Events

Date Code Title Description
EG Technical examination (opinion): publication of technical examination (opinion)
B09B Patent application refused [chapter 9.2 patent gazette]
B12B Appeal against refusal [chapter 12.2 patent gazette]